Literature DB >> 2306409

Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?

J R Hughes1, S G Bowes, A L Leeman, C J O'Neill, A A Deshmukh, P W Nicholson, S M Dobbs, R J Dobbs.   

Abstract

1. Normally during walking, the heel strikes the ground before the forefoot. Abnormalities of foot strike in idiopathic Parkinson's disease may be amenable to therapy: objective measurements may reveal response which is not clinically apparent. Occult changes in foot strike leading to instability may parallel the normal, age-related loss of striatal dopamine. 2. The nature of foot strike was studied using pedobarography in 160 healthy volunteers, aged 15 to 91 years. Although 16% of strikes were made simultaneously by heel and forefoot, there were no instances of the forefoot preceding the heel. No significant effect of age on an index of normality of foot strikes was detected (P greater than 0.3). 3. The effect on foot strike of substituting placebo for a morning dose of a levodopa/carbidopa combination was studied in a double-blind, cross-over trial in 14 patients, aged 64 to 88 years, with no overt fluctuations in control of their idiopathic Parkinson's disease in relation to dosing. On placebo treatment there was a highly significant (P = 0.004) reduction in the number of more normal strikes, i.e. heel strikes plus simultaneous heel and forefoot strikes. The effect appeared unrelated to the corresponding difference between active and placebo treatments in plasma concentration of levodopa or a metabolite of long half-time, 3-O-methyldopa (3OMD). However, it correlated negatively (P less than 0.05) with the mean of the 3OMD concentrations. 4. It appears that some abnormalities of foot strike due to Parkinson's disease are reversible. Employing test conditions, designed to provoke abnormalities of foot strike, might be useful in screening for pre-clinical Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306409      PMCID: PMC1380081          DOI: 10.1111/j.1365-2125.1990.tb03617.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  Life Sci       Date:  1975-07-01       Impact factor: 5.037

2.  Patterns of clinical response and plasma dopa levels in Parkinson's disease.

Authors:  E S Tolosa; W E Martin; H P Cohen; R L Jacobson
Journal:  Neurology       Date:  1975-02       Impact factor: 9.910

3.  Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.

Authors:  R D Sweet; F H McDowell
Journal:  Neurology       Date:  1974-10       Impact factor: 9.910

4.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

5.  DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.

Authors:  T A Hare; B L Beasley; R A Chambers; D H Boehme; W H Vogel
Journal:  Clin Chim Acta       Date:  1973-05-18       Impact factor: 3.786

6.  Plasma concentration of levodopa in patients with Parkinson's disease.

Authors:  U K Rinne; V Sonninen; T Siirtola
Journal:  Eur Neurol       Date:  1973       Impact factor: 1.710

7.  Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

Authors:  M D Muenter; N S Sharpless; G M Tyce
Journal:  Mayo Clin Proc       Date:  1972-06       Impact factor: 7.616

Review 8.  Gait as a total pattern of movement.

Authors:  M P Murray
Journal:  Am J Phys Med       Date:  1967-02

9.  The metabolism of L-3-O-methyldopa, a precursor of dopa in man.

Authors:  I Kuruma; G Bartholini; R Tissot; A Pletscher
Journal:  Clin Pharmacol Ther       Date:  1971 Jul-Aug       Impact factor: 6.875

10.  Bringing gait analysis out of the laboratory and into the clinic.

Authors:  L Klenerman; R J Dobbs; C Weller; A L Leeman; P W Nicholson
Journal:  Age Ageing       Date:  1988-11       Impact factor: 10.668

View more
  8 in total

1.  Characteristics of the electromyographic patterns of lower limb muscles during gait in patients with Parkinson's disease when OFF and ON L-Dopa treatment.

Authors:  M Cioni; C L Richards; F Malouin; P J Bedard; R Lemieux
Journal:  Ital J Neurol Sci       Date:  1997-08

2.  Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.

Authors:  C Weller; C J O'Neill; A Charlett; S G Bowes; A Purkiss; P W Nicholson; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

3.  Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.

Authors:  S G Bowes; C J O'Neill; P W Nicholson; A L Leeman; A A Deshmukh; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.

Authors:  S G Bowes; R J Dobbs; M Henley; A Charlett; C J O'Neill; P W Nicholson; A G Purkiss; C Weller; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  A computational model of altered gait patterns in parkinson's disease patients negotiating narrow doorways.

Authors:  Vignesh Muralidharan; Pragathi P Balasubramani; V Srinivasa Chakravarthy; Simon J G Lewis; Ahmed A Moustafa
Journal:  Front Comput Neurosci       Date:  2014-01-09       Impact factor: 2.380

6.  Kinematic and Kinetic Patterns Related to Free-Walking in Parkinson's Disease.

Authors:  Martín Martínez; Federico Villagra; Juan Manuel Castellote; María A Pastor
Journal:  Sensors (Basel)       Date:  2018-12-01       Impact factor: 3.576

7.  Proof of Concept in Artificial-Intelligence-Based Wearable Gait Monitoring for Parkinson's Disease Management Optimization.

Authors:  Robert Radu Ileșan; Claudia-Georgiana Cordoș; Laura-Ioana Mihăilă; Radu Fleșar; Ana-Sorina Popescu; Lăcrămioara Perju-Dumbravă; Paul Faragó
Journal:  Biosensors (Basel)       Date:  2022-03-23

8.  Measuring Gait Quality in Parkinson's Disease through Real-Time Gait Phase Recognition.

Authors:  Ilaria Mileti; Marco Germanotta; Enrica Di Sipio; Isabella Imbimbo; Alessandra Pacilli; Carmen Erra; Martina Petracca; Stefano Rossi; Zaccaria Del Prete; Anna Rita Bentivoglio; Luca Padua; Eduardo Palermo
Journal:  Sensors (Basel)       Date:  2018-03-20       Impact factor: 3.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.